Barclays’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $47.4M | Sell |
932,269
-610,188
| -40% | -$28.5M | 0.01% | 745 |
|
|
2025
Q4 | $45.5M | Sell |
1,542,457
-473,371
| -23% | -$12.9M | 0.01% | 823 |
|
|
2025
Q3 | $52.1M | Sell |
2,015,828
-171,399
| -8% | -$4.78M | 0.01% | 750 |
|
|
2025
Q2 | $60.3M | Buy |
2,187,227
+763,450
| +54% | +$20.1M | 0.01% | 642 |
|
|
2025
Q1 | $40.4M | Buy |
1,423,777
+227,838
| +19% | +$8.09M | 0.01% | 733 |
|
|
2024
Q4 | $49.7M | Sell |
1,195,939
-336,873
| -22% | -$16.1M | 0.01% | 667 |
|
|
2024
Q3 | $102M | Buy |
1,532,812
+193,059
| +14% | +$17.7M | 0.03% | 429 |
|
|
2024
Q2 | $159M | Buy |
1,339,753
+146,856
| +12% | +$18.6M | 0.05% | 277 |
|
|
2024
Q1 | $127M | Buy |
1,192,897
+84,733
| +8% | +$8.54M | 0.04% | 322 |
|
|
2023
Q4 | $110M | Buy |
1,108,164
+163,264
| +17% | +$13.7M | 0.04% | 384 |
|
|
2023
Q3 | $97.6M | Buy |
944,900
+34,008
| +4% | +$3.79M | 0.06% | 321 |
|
|
2023
Q2 | $111M | Buy |
910,892
+256,295
| +39% | +$34.2M | 0.07% | 252 |
|
|
2023
Q1 | $101M | Sell |
654,597
-813,653
| -55% | -$134M | 0.05% | 264 |
|
|
2022
Q4 | $264M | Sell |
1,468,250
-120,454
| -8% | -$19.7M | 0.12% | 131 |
|
|
2022
Q3 | $188M | Buy |
1,588,704
+399,454
| +34% | +$60.6M | 0.21% | 105 |
|
|
2022
Q2 | $170M | Sell |
1,189,250
-124,917
| -10% | -$17.9M | 0.1% | 153 |
|
|
2022
Q1 | $226M | Sell |
1,314,167
-1,987,952
| -60% | -$335M | 0.18% | 123 |
|
|
2021
Q4 | $839M | Buy |
3,302,119
+2,047,118
| +163% | +$599M | 0.31% | 56 |
|
|
2021
Q3 | $483M | Buy |
1,255,001
+657,299
| +110% | +$242M | 0.22% | 74 |
|
|
2021
Q2 | $140M | Buy |
597,702
+185,034
| +45% | +$33.1M | 0.07% | 229 |
|
|
2021
Q1 | $54M | Sell |
412,668
-190,618
| -32% | -$27.6M | 0.03% | 427 |
|
|
2020
Q4 | $63M | Sell |
603,286
-189,310
| -24% | -$19.2M | 0.03% | 385 |
|
|
2020
Q3 | $56.1M | Buy |
792,596
+356,811
| +82% | +$24.9M | 0.03% | 368 |
|
|
2020
Q2 | $28M | Buy |
435,785
+322,685
| +285% | +$17.7M | 0.02% | 510 |
|
|
2020
Q1 | $3.39M | Buy |
113,100
+94,258
| +500% | +$2.17M | ﹤0.01% | 1806 |
|
|
2019
Q4 | $369K | Sell |
18,842
-9,163
| -33% | -$163K | ﹤0.01% | 4549 |
|
|
2019
Q3 | $446K | Sell |
28,005
-14,125
| -34% | -$209K | ﹤0.01% | 4339 |
|
|
2019
Q2 | $617K | Sell |
42,130
-30,701
| -42% | -$659K | ﹤0.01% | 4139 |
|
|
2019
Q1 | $1.48M | Buy |
+72,831
| New | +$1.35M | ﹤0.01% | 2941 |
|
Other funds holding MRNA
VCM
VPM
Barclays's MRNA Position: Q1 2026 in Review
Barclays reduced its Moderna (MRNA) stake by 40% in Q1 2026, selling an estimated $28.5M and leaving 932,269 shares worth $47.4M. The position accounts for 0.01% of the portfolio, ranked #745.
Barclays first reported a position in MRNA in Q1 2019 and has held it in 29 quarters since. The position peaked at $839M in Q4 2021. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.
- Barclays held 932,269 shares of Moderna worth $47.4M as of Q1 2026.
- Barclays sold 610,188 Moderna shares in Q1 2026, an estimated $28.5M.
- Moderna made up 0.01% of Barclays's portfolio in Q1 2026, its #745 holding.
- Barclays first reported a position in Moderna in Q1 2019 and has held it in 29 quarters since.
- Barclays's Moderna position peaked at $839M in Q4 2021.
- 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.